BioPharma Dive June 21, 2021
Study results are expected for CRISPR gene editing, the treatment of COVID-19, microbiome drugs and gene-targeted cancer therapy.
The first half of 2021 was historic for biotech. The Food and Drug Administration cleared the first new Alzheimer’s drug in nearly two decades, a controversial decision with far-reaching consequences. Multiple effective coronavirus vaccines and antibody drugs helped bring the pandemic under control in the U.S., while the first-ever treatment for a common genetic driver...
Today's Sponsors
Today's Sponsor